Diagnosis and differential diagnosis of multiple myelomas

Multiple myeloma (MM) is a hematologic malignancy characterized by the clonal proliferation of plasma cells within the bone marrow, leading to the overproduction of monoclonal immunoglobulins (M-proteins). This disease can result in various clinical manifestations, including bone lesions, anemia, renal dysfunction, and immunodeficiency.

Clinical Presentation

Patients with MM may present with a range of symptoms and laboratory abnormalities:

• Bone Pain: Often due to osteolytic lesions, commonly affecting the spine and ribs.
• Hypercalcemia: Resulting from bone resorption, leading to symptoms like nausea, vomiting, constipation, and confusion.
• Renal Impairment: Caused by light chain deposition, hypercalcemia, or hyperuricemia.
• Anemia: Due to marrow infiltration by malignant plasma cells and decreased erythropoiesis.
• Infections: Increased susceptibility due to impaired normal immunoglobulin production.

Diagnostic Criteria

According to the International Myeloma Working Group (IMWG), the diagnosis of MM requires:

1. Clonal Bone Marrow Plasma Cells: ≥10% or biopsy-proven plasmacytoma.
2. Myeloma-Defining Events (MDEs): At least one of the following:

• CRAB Features:
  • Calcium elevation: Serum calcium >11 mg/dL (>2.75 mmol/L).
  • Renal insufficiency: Serum creatinine >2 mg/dL or creatinine clearance <40 mL/min.
  • Anemia: Hemoglobin <10 g/dL or >2 g/dL below the normal limit.
  • Bone lesions: One or more osteolytic lesions on imaging.
• Biomarkers:
  • Clonal bone marrow plasma cells ≥60%.
  • Involved/uninvolved serum free light chain ratio ≥100, with involved light chain ≥100 mg/L.
  • More than one focal lesion ≥5 mm on MRI.

Laboratory and Imaging Studies

• Complete Blood Count (CBC): To assess for anemia and leukopenia.
• Serum Chemistry Panel: Including calcium, creatinine, and albumin levels.
• Serum and Urine Protein Electrophoresis (SPEP and UPEP): To detect M-proteins.
• Immunofixation Electrophoresis: To identify the type of monoclonal protein.
• Serum Free Light Chain Assay: To quantify kappa and lambda light chains.
• Bone Marrow Biopsy: To determine the percentage of plasma cell infiltration.
• Imaging:
  • Skeletal Survey: To identify lytic bone lesions.
  • MRI or PET-CT: For detailed assessment of bone marrow involvement and extramedullary disease.

Staging Systems

Durie-Salmon Staging System

An older system based on clinical and laboratory parameters:

• Stage I: Low M-protein levels, normal calcium, hemoglobin >10 g/dL, normal bone structure.
• Stage II: Intermediate findings.
• Stage III: High M-protein levels, hypercalcemia, hemoglobin <8.5 g/dL, advanced lytic bone lesions.

International Staging System (ISS)

A more recent system utilizing

• Stage I: Serum β2-microglobulin <3.5 mg/L and serum albumin ≥3.5 g/dL.
• Stage II: Neither Stage I nor Stage III criteria met.
• Stage III: Serum β2-microglobulin ≥5.5 mg/L.

Differential Diagnosis

Monoclonal Gammopathy of Undetermined Significance (MGUS)

• Serum M-protein: <3 g/dL.
• Bone Marrow Plasma Cells: <10%.
• No CRAB Features: Absence of end-organ damage.

Smoldering Multiple Myeloma (SMM)

• Serum M-protein: ≥3 g/dL and/or bone marrow plasma cells 10–60%.
• No CRAB Features: Asymptomatic with no end-organ damage.

Primary Amyloidosis (AL)

• Organ Involvement: Cardiac, renal, hepatic, or peripheral nervous system.
• Laboratory Findings: Presence of monoclonal light chains; confirmed by tissue biopsy with Congo red staining.

Metastatic Carcinoma

• Bone Lesions: Can mimic MM lytic lesions.
• Differentiation: Requires imaging, biopsy, and immunohistochemical staining to identify primary tumor origin.

Plasma Cell Leukemia (PCL)

A rare and aggressive variant of MM characterized by:

• Peripheral Blood Plasma Cells:
  • 2 × 10^9/L or >20% of leukocytes.
• Clinical Features: More aggressive disease with extramedullary involvement, anemia, thrombocytopenia, and renal dysfunction.
• Treatment: Requires prompt initiation of combination chemotherapy, often including proteasome inhibitors (e.g., bortezomib) and immunomodulatory agents (e.g., lenalidomide), followed by consideration of autologous stem cell transplantation

---